| Active sites of human MEPE-ASARM regulating bone matrix mineralization. | Active sites of human MEPE-ASARM regulating bone matrix mineralization.
Minamizaki T, Sakurai K, Hayashi I, Toshishige M, Yoshioka H, Kozai K, Yoshiko Y. | 07/10/2021 |
| MEPE loss-of-function variant associates with decreased bone mineral density and increased fracture risk. | MEPE loss-of-function variant associates with decreased bone mineral density and increased fracture risk.
Surakka I, Fritsche LG, Zhou W, Backman J, Kosmicki JA, Lu H, Brumpton B, Nielsen JB, Gabrielsen ME, Skogholt AH, Wolford B, Graham SE, Chen YE, Lee S, Kang HM, Langhammer A, Forsmo S, Åsvold BO, Styrkarsdottir U, Holm H, Gudbjartsson D, Stefansson K, Baras A, Regeneron Genetics Center, Abecasis GR, Hveem K, Willer CJ., Free PMC Article | 11/21/2020 |
| sequencing identified a rare segregating heterozygous frameshift variant p.(Gln425Lysfs*38) in MEPE. We performed variant burden and variance components analyses in a large otosclerosis cohort and demonstrated that nonsense and frameshift MEPE variants were significantly enriched in affected subjects (p = 0.0006-0.0060). | Variants affecting diverse domains of MEPE are associated with two distinct bone disorders, a craniofacial bone defect and otosclerosis.
Schrauwen I, Valgaeren H, Tomas-Roca L, Sommen M, Altunoglu U, Wesdorp M, Beyens M, Fransen E, Nasir A, Vandeweyer G, Schepers A, Rahmoun M, van Beusekom E, Huentelman MJ, Offeciers E, Dhooghe I, Huber A, Van de Heyning P, Zanetti D, De Leenheer EMR, Gilissen C, Hoischen A, Cremers CW, Verbist B, de Brouwer APM, Padberg GW, Pennings R, Kayserili H, Kremer H, Van Camp G, van Bokhoven H. | 02/15/2020 |
| Results indicate an association of MEPE gene inactivation with decreased survival after DNA damage. | MicroRNA-376a sensitizes cells following DNA damage by downregulating MEPE expression.
Sheng J, Luo W, Yu F, Gao N, Hu B., Free PMC Article | 05/17/2014 |
| Mice deficient in an ortholog of MEPE show increased bone mass and are resistant to aging-related bone loss. | Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass.
Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. | 03/27/2014 |
| results indicated that MEPE appeared to play an important positive role in proliferation and osteogenesis differentiation of DPCs through interaction with downstream signals. | The effect of matrix extracellular phosphoglycoprotein and its downstream osteogenesis-related gene expression on the proliferation and differentiation of human dental pulp cells.
Wei X, Liu L, Zhou X, Zhang F, Ling J. | 07/21/2012 |
| MEPE or the MEPE-derived acidic serine aspartate-rich MEPE-associated motif peptide may contribute to decreased bone mineralization in Oncogenic osteomalacia patients. | Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.
Imanishi Y, Hashimoto J, Ando W, Kobayashi K, Ueda T, Nagata Y, Miyauchi A, Koyano HM, Kaji H, Saito T, Oba K, Komatsu Y, Morioka T, Mori K, Miki T, Inaba M. | 05/19/2012 |
| Among migraineurs with aura rs7698623 in MEPE (OR = 6.37; 95% CI 3.15-12.90; p = 2.7x10(-7)) and rs4975709 in IRX4 (OR = 5.06; 95% CI 2.66-9.62; p = 7.7x10(-7)) appeared to be associated with ischemic stroke. | Genetic determinants of cardiovascular events among women with migraine: a genome-wide association study.
Schürks M, Buring JE, Ridker PM, Chasman DI, Kurth T., Free PMC Article | 11/19/2011 |
| Sclerostin acts through regulation of the PHEX/MEPE axis at the preosteocyte stage and serves as a master regulator of physiologic bone mineralization. | Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM., Free PMC Article | 10/15/2011 |
| MEPE may play a regulatory role in periodontal ligament cell osteogenic differentiation. | [Expression of matrix extracellular phosphoglycoprotein mRNA in human periodontal ligament cell osteogenic differentiation].
Wu LP, Wei X, Ling JQ, Liu L. | 03/12/2011 |
| These results suggest that abnormal MEPE cleavage occurs when PHEX activity is deficient in humans. | Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.
Boukpessi T, Gaucher C, Léger T, Salmon B, Le Faouder J, Willig C, Rowe PS, Garabédian M, Meilhac O, Chaussain C., Free PMC Article | 01/29/2011 |
| This study demonstrates the importance of posttranslational modification for the site-specific activity of MEPE and its ASARM peptide. | MEPE's diverse effects on mineralization.
Boskey AL, Chiang P, Fermanis A, Brown J, Taleb H, David V, Rowe PS., Free PMC Article | 05/3/2010 |
| The patterns of expression of FGF-23, MEPE, and DMP1 differ markedly in trabecular bone, suggesting that individual osteocytes may have specialized functions. | Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K., Free PMC Article | 02/1/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men.
Yerges LM, Klei L, Cauley JA, Roeder K, Kammerer CM, Moffett SP, Ensrud KE, Nestlerode CS, Marshall LM, Hoffman AR, Lewis C, Lang TF, Barrett-Connor E, Ferrell RE, Orwoll ES, Zmuda JM, MrOS Research Group., Free PMC Article | 06/24/2009 |
| MEPE is a candidate phosphatonin involved in phosphate homeostasis, acting in both the kidney and the gastrointestinal tract | Matrix extracellular phosphoglycoprotein inhibits phosphate transport.
Marks J, Churchill LJ, Debnam ES, Unwin RJ., Free PMC Article | 01/21/2010 |
| MEPE expression is higher when cells proliferate, whereas it is downregulated as cells differentiated | Changes in matrix extracellular phosphoglycoprotein expression before and during in vitro osteogenic differentiation of human dental papilla mesenchymal cells.
Tetè S, Nargi E, Mastrangelo F, Zizzari V, D'Apolito G, Traini T, Costanzo G, Dadorante V, D'Alimonte I, Caputi S, Caciagli F, Ciccarelli R. | 01/21/2010 |
| MEPE is predominantly expressed by osteocytes in human bone, with significant expression by osteocytes within mineralized bone | Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone.
Nampei A, Hashimoto J, Hayashida K, Tsuboi H, Shi K, Tsuji I, Miyashita H, Yamada T, Matsukawa N, Matsumoto M, Morimoto S, Ogihara T, Ochi T, Yoshikawa H. | 01/21/2010 |
| The results are consistent with MEPE being involved in phosphate and bone metabolism in a normal population. | Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density.
Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW. | 01/21/2010 |
| There is evidence for a hormone/enzyme/extracellular matrix protein cascade involving fibroblastic growth factor 23 (FGF23), a phosphate-regulating gene with homologies to (PHEX) and (MEPE)--REVIEW | FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD. | 01/21/2010 |
| MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21. Expressed during odontogenesis. | MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21.
MacDougall M, Simmons D, Gu TT, Dong J. | 01/21/2010 |
| MEPE is expressed in salivary gland ducts. | Expression of SIBLINGs and their partner MMPs in salivary glands.
Ogbureke KU, Fisher LW. | 09/26/2006 |
| MEPE is expressed on the luminal surface of kidney proximal tubules. | Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs).
Ogbureke KU, Fisher LW. | 09/26/2006 |